September 2000
Science Teacher;Sep2000, Vol. 67 Issue 6, p14
Academic Journal
Reports on the clinical trials conducted by Sewon Kang and colleagues on the effectiveness of certain ultraviolet light in treating patients with scleroderma. Discoveries about the effects of different kinds of ultraviolet light on the skin; Causes of scleroderma.


Related Articles

  • Topical Photodynamic Therapy for Localized Scleroderma. Karrer, Sigrid; Abels, Christoph; Landthaler, Michael; Szeimies, Rolf-Markus // Acta Dermato-Venereologica;Jan2000, Vol. 80 Issue 1, p26 

    Therapy of localized scleroderma is unsatisfactory, with numerous treatments being used that have only limited success or considerable side-effects. The aim of this trial was to determine whether topical photodynamic therapy would be effective in patients with localized scleroderma. Five...

  • Rays of hope. Munson, Marty; Higbee, Beth // Prevention;Dec94, Vol. 46 Issue 12, p46 

    Explains that artificial sunlight may hold promise against the debilitating skin disease, scleroderma. Case study of two patients which found sun lamps effective where drugs weren't in treating the localized form of the disease; Report in `Lancet,' May 14, 1994; PUVA treatment.

  • Relaxin hormone may hold promise for scleroderma. Moyer, Paula // Dermatology Times;Jul95, Vol. 16 Issue 7, p52 

    Reports on the potential of human relaxin hormone in the treatment of fibrotic diseases including scleroderma, according to Edward P. Amento. Probable mechanism of action; Connective Therapeutics' development of recombinant relaxin.

  • New treatment may be coming for scleroderma.  // Dermatology Times;Aug97, Vol. 18 Issue 8, p3 

    Presents the results from Connetics Corp.'s trial which suggests that recombinant human relaxin H2 (ConXn) may be an effective treatment for scleroderma. Information on how the study was conducted.

  • Photochemotherapy Relieves Case of Graft vs. Host Disease. Wilson, Fred // Dermatology Times;Apr2000, Vol. 21 Issue 4, p16 

    Reports that a bone marrow transplant recipient with chronic sclerodermic graft-versus-host disease has shown strong response to UVA1 phototherapy combined with myophenolate mofetil immunosuppressive therapy. Details of the medical case; Adverse effects of UVA1.

  • Treatment of Gi dysmotility in scleroderma with the new enterokinetic agent prucalopride. Boeckxstaens, G.E.; Bartelsman, J.F.W.M.; Lauwers, L.; Tytgat, G.N.J. // American Journal of Gastroenterology;Jan2002, Vol. 97 Issue 1, p194 

    Scleroderma is a multisystem disorder frequently resulting in disturbed GI motility. Although, especially early in the disease, symptomatic improvement is achieved with prokinetic agents, more severe GI manifestations of scleroderma may be difficult to treat, leading to parenteral feeding and...

  • Scleroderma. Dunkin, Mary Anne // Arthritis Today;Nov/Dec97, Vol. 11 Issue 6, p16 

    Focuses on an arthritis-related disease called scleroderma. When it occurs; Amount of forms it can be divided into; Information on how scleroderma is treated.

  • Acne drug can stop deadly disease.  // Current Science;9/25/98, Vol. 84 Issue 2, p14 

    Reports on the effectiveness of minocycline, an acne medication, against scleroderma, a skin disease. Estimated amount of Americans the disease affects; Where in the body scleroderma affects; Comments from David Trentham, a doctor at Beth Israel Deaconess Medical Center in Boston,...

  • Ultraviolet A Sunbed Used for the Treatment of Scleroderma. Oikarinen, Aarne; Knuutinen, Anina // Acta Dermato-Venereologica;Nov/Dec2001, Vol. 81 Issue 6, p432 

    Examines the efficacy of ultraviolet A (UVA) treatment on Scleroderma Influence of UVA on the increase collagenase mechanism in fibroblast cultures in human skin; Contribution of modulation of immunosystem by UVA on the treatment of the disease; Assessment on the side effects of the treatment.

  • Gemcitabine-induced Acute Lipodermatosclerosis-like Reaction. Chu, Chia-Yu; Yang, Chih-Hsin; Chiu, Hsien-Ching // Acta Dermato-Venereologica;Nov/Dec2001, Vol. 81 Issue 6, p426 

    Gemcitabine is considered to be a well-tolerated and safe cytostatic drug because of the relative lack of side effects. Cutaneous reactions due to gemcitabine treatment, including alopecia and maculopapular eruption, are well known. We report one patient with squamous cell carcinoma of the lung...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics